Literature DB >> 23205057

Experience with sorafenib in the treatment of advanced renal cell carcinoma.

Giuseppe Procopio1, Elena Verzoni, Isabella Testa, Nicola Nicolai, Roberto Salvioni, Filippo Debraud.   

Abstract

The molecular-targeted agent sorafenib is the first anticancer agent able to slow the progression of advanced/metastatic renal cell carcinoma, a tumor that was formerly refractory to conventional therapy. Experience from everyday clinical practice and investigations exploring the suitability of this agent for patients with harmful pathological conditions has extended the use of sorafenib to other settings of renal cell carcinoma and to particular risk populations. The aim of this review is to provide evidence on the most effective and safe use of sorafenib. The review pays particular attention to patients who have several comorbidities, such as impaired renal and cardiac function, and older patients whose frailty due to impaired organ function necessitates the most careful administration of targeted antineoplastic agents.

Entities:  

Keywords:  First-line treatment; older people; renal cell carcinoma; sorafenib; targeted therapies

Year:  2012        PMID： 23205057      PMCID： PMC3491759          DOI： 10.1177/1756287212457216

Source DB:  PubMed          Journal:  Ther Adv Urol        ISSN： 1756-2872


  45 in total

1.  Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study.

Authors:  Keiko Shinsako; Tomoyuki Mizuno; Tomohiro Terada; Jun Watanabe; Tomomi Kamba; Eijiro Nakamura; Osamu Ogawa; Ken-ichi Inui
Journal:  Int J Clin Oncol       Date:  2010-03-26       Impact factor: 3.402

2.  A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.

Authors:  Joaquim Bellmunt; Pablo Maroto-Rey; José M Trigo; Joan Carles; Vicente Guillem; José A López-Martín; Antonio Antón-Torres; Leyrer Urruticoechea
Journal:  Clin Transl Oncol       Date:  2010-07       Impact factor: 3.405

3.  Sustained response following sorafenib therapy in an older adult patient with advanced renal cancer on hemodialysis: a case report.

Authors:  B Castagneto; I Stevani; L Giorcelli; F Montefiore; G L Bigatti; P Pisacco; M F Cosimi
Journal:  Med Oncol       Date:  2010-06-15       Impact factor: 3.064

4.  Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.

Authors:  Bernard Escudier; Cezary Szczylik; Thomas E Hutson; Tomasz Demkow; Michael Staehler; Frédéric Rolland; Sylvie Negrier; Nicole Laferriere; Urban J Scheuring; David Cella; Sonalee Shah; Ronald M Bukowski
Journal:  J Clin Oncol       Date:  2009-01-26       Impact factor: 44.544

5.  Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.

Authors:  Martin E Gore; Cezary Szczylik; Camillo Porta; Sergio Bracarda; Georg A Bjarnason; Stéphane Oudard; Subramanian Hariharan; Se-Hoon Lee; John Haanen; Daniel Castellano; Eduard Vrdoljak; Patrick Schöffski; Paul Mainwaring; Alejandra Nieto; Jinyu Yuan; Ronald Bukowski
Journal:  Lancet Oncol       Date:  2009-07-15       Impact factor: 41.316

6.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Authors:  Gary Hudes; Michael Carducci; Piotr Tomczak; Janice Dutcher; Robert Figlin; Anil Kapoor; Elzbieta Staroslawska; Jeffrey Sosman; David McDermott; István Bodrogi; Zoran Kovacevic; Vladimir Lesovoy; Ingo G H Schmidt-Wolf; Olga Barbarash; Erhan Gokmen; Timothy O'Toole; Stephanie Lustgarten; Laurence Moore; Robert J Motzer
Journal:  N Engl J Med       Date:  2007-05-31       Impact factor: 91.245

7.  Experience with sorafenib and the elderly patient.

Authors:  Janice P Dutcher; Nizar Tannir; Joaquim Bellmunt; Bernard Escudier
Journal:  Med Oncol       Date:  2009-12-31       Impact factor: 3.064

Review 8.  EORTC-GU group expert opinion on metastatic renal cell cancer.

Authors:  Theo M de Reijke; Joaquim Bellmunt; Hein van Poppel; Sandrine Marreaud; Matti Aapro
Journal:  Eur J Cancer       Date:  2009-01-20       Impact factor: 9.162

9.  A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.

Authors:  Anthony W Tolcher; Leonard J Appleman; Geoffrey I Shapiro; Alain C Mita; Frank Cihon; Arthur Mazzu; Pavur R Sundaresan
Journal:  Cancer Chemother Pharmacol       Date:  2010-06-03       Impact factor: 3.333

10.  Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial.

Authors:  G Procopio; E Verzoni; S Bracarda; S Ricci; C Sacco; L Ridolfi; C Porta; R Miceli; N Zilembo; E Bajetta
Journal:  Br J Cancer       Date:  2011-03-29       Impact factor: 7.640
View more
  11 in total

Review 1.  The lymphatic system and pancreatic cancer.

Authors:  Darci M Fink; Maria M Steele; Michael A Hollingsworth
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

2.  Efficacy of sorafenib correlates with Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification and bone metastasis in Chinese patients with metastatic renal cell carcinoma.

Authors:  Yushi Zhang; Yongqiang Li; Yi Cai; Ke Wang; Hanzhong Li
Journal:  Cell Oncol (Dordr)       Date:  2015-11-23       Impact factor: 6.730

Review 3.  Lymphangiogenesis and lymphatic vessel remodelling in cancer.

Authors:  Steven A Stacker; Steven P Williams; Tara Karnezis; Ramin Shayan; Stephen B Fox; Marc G Achen
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

Review 4.  Lymphovascular and neural regulation of metastasis: shared tumour signalling pathways and novel therapeutic approaches.

Authors:  Caroline P Le; Tara Karnezis; Marc G Achen; Steven A Stacker; Erica K Sloan
Journal:  Best Pract Res Clin Anaesthesiol       Date:  2013-10-15

Review 5.  Comparing comparators: a look at control arms in kidney cancer studies over the years.

Authors:  S Bracarda; C Porta; M Sisani; F Marrocolo; C Paglino; A Hamzaj; S D Buono; C N Sternberg
Journal:  Br J Cancer       Date:  2014-11-06       Impact factor: 7.640

6.  A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404).

Authors:  Daniel R Greenwald; Hailun Li; Selina M Luger; Ronald S Go; David King; Taral Patel; Randy D Gascoyne; Jill Kolesar; Brad S Kahl; Sandra Horning
Journal:  J Hematol Oncol       Date:  2013-07-05       Impact factor: 17.388

7.  Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer.

Authors:  Núria Eritja; Bo-Juen Chen; Ruth Rodríguez-Barrueco; Maria Santacana; Sònia Gatius; August Vidal; Maria Dolores Martí; Jordi Ponce; Laura Bergadà; Andree Yeramian; Mario Encinas; Joan Ribera; Jaume Reventós; Jeff Boyd; Alberto Villanueva; Xavier Matias-Guiu; Xavier Dolcet; David Llobet-Navàs
Journal:  Autophagy       Date:  2017-01-05       Impact factor: 16.016

Review 8.  Role of lymphatic endothelial cells in the tumor microenvironment-a narrative review of recent advances.

Authors:  Miao He; Qihua He; Xiuyu Cai; Zisheng Chen; Shen Lao; Hongsheng Deng; Xiwen Liu; Yongmei Zheng; Xiaoyan Liu; Jun Liu; Zhanhong Xie; Maojin Yao; Wenhua Liang; Jianxing He
Journal:  Transl Lung Cancer Res       Date:  2021-05

Review 9.  Platelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers.

Authors:  Kwaku Appiah-Kubi; Ying Wang; Hai Qian; Min Wu; Xiaoyuan Yao; Yan Wu; Yongchang Chen
Journal:  Tumour Biol       Date:  2016-05-19

Review 10.  Abnormal Iron and Lipid Metabolism Mediated Ferroptosis in Kidney Diseases and Its Therapeutic Potential.

Authors:  Xiaoqin Zhang; Xiaogang Li
Journal:  Metabolites       Date:  2022-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.